Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797009 | 0.76 | — | — | |
| SCHEMBL332661 | 0.69 | CA2 (0.34) | CA1CA2 | |
| SCHEMBL1799467 | 0.68 | IDO1 (0.34) | CA12CA1CA2CA3CA4 | |
| SCHEMBL27629298 | 0.67 | RECQL (0.34) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1523769 | 0.67 | CA2 (0.41) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL1523284 | 0.64 | — | — | |
| SCHEMBL27842568 | 0.62 | CA1 (0.34) | CA12CA1CA2CA9CA14 | |
| SCHEMBL14311387 | 0.61 | MAPT (0.32) | — | |
| SCHEMBL27629522 | 0.58 | VCAM1 (0.45) | CA12CA1CA2CA3CA4 | |
| SCHEMBL21224681 | 0.57 | CA2 (0.38) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815847-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | ANADYS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| CN-102316871-B | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS INC | 2014-06-04 | — | — | CN | disclosed |
| CN-103827100-A | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | ANADYS PHARMACEUTICALS INC | 2014-05-28 | — | — | CN | disclosed |
| EP-2718273-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | Anadys Pharmaceuticals, Inc. (US) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012170536-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | ANADYS PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | ANADYS PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-8222404-B2 | [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8097613-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| CN-102316871-A | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS INC | 2012-01-11 | — | — | CN | disclosed |
| US-7951800-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100120753-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-7662958-B2 | e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis | ABBVIE INC. | 2010-02-16 | — | — | US | disclosed |
| WO-2009152166-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008011337-A1 | HCV INHIBITORS | ABBOTT LABORATORIES (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ACMSD, ACACA, ALDH1A1 | CA12 473/4885CA1 444/4885CA2 436/4885 |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | NQO2, RSU1, RRS1 | CA12 4833/4885CA1 4775/4885CA2 3689/4885 |
| US-20100120753-A1 | Anti-Infective Agents | RSU1, NQO2, RRS1 | CA12 4846/4885CA1 4785/4885CA2 3663/4885 |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | THOP1, XDH, DUOX1 | CA12 1285/4885CA1 1252/4885CA2 721/4885 |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | CYP2E1, CYP1A1, CYP1B1 | CA12 2445/4885CA1 3677/4885CA2 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.